Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.74
STXS's Cash to Debt is ranked higher than
62% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. STXS: 0.74 )
STXS' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: 0.74

Equity to Asset -0.38
STXS's Equity to Asset is ranked lower than
56% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. STXS: -0.38 )
STXS' s 10-Year Equity to Asset Range
Min: -0.58   Max: 0.82
Current: -0.38

-0.58
0.82
F-Score: 4
Z-Score: -20.64
M-Score: -5.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -23.24
STXS's Operating margin (%) is ranked higher than
54% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. STXS: -23.24 )
STXS' s 10-Year Operating margin (%) Range
Min: -113273.68   Max: -22.82
Current: -23.24

-113273.68
-22.82
Net-margin (%) -180.79
STXS's Net-margin (%) is ranked lower than
53% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. STXS: -180.79 )
STXS' s 10-Year Net-margin (%) Range
Min: -112942.11   Max: -19.84
Current: -180.79

-112942.11
-19.84
ROA (%) -221.26
STXS's ROA (%) is ranked lower than
57% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. STXS: -221.26 )
STXS' s 10-Year ROA (%) Range
Min: -221.26   Max: -28.72
Current: -221.26

-221.26
-28.72
ROC (Joel Greenblatt) (%) -745.99
STXS's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. STXS: -745.99 )
STXS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3074.57   Max: -381.69
Current: -745.99

-3074.57
-381.69
Revenue Growth (%) -32.50
STXS's Revenue Growth (%) is ranked lower than
52% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. STXS: -32.50 )
STXS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 218.6
Current: -32.5

0
218.6
EBITDA Growth (%) 17.20
STXS's EBITDA Growth (%) is ranked higher than
87% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. STXS: 17.20 )
STXS' s 10-Year EBITDA Growth (%) Range
Min: -72   Max: 17.2
Current: 17.2

-72
17.2
EPS Growth (%) 14.70
STXS's EPS Growth (%) is ranked higher than
84% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. STXS: 14.70 )
STXS' s 10-Year EPS Growth (%) Range
Min: -57.7   Max: 14.7
Current: 14.7

-57.7
14.7
» STXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

STXS Guru Trades in Q4 2012

Jim Simons 45,042 sh (+127%)
» More
Q1 2013

STXS Guru Trades in Q1 2013

Jim Simons 58,842 sh (+30.64%)
» More
Q2 2013

STXS Guru Trades in Q2 2013

Jim Simons 48,842 sh (-16.99%)
» More
Q3 2013

STXS Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with STXS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 1.10
STXS's P/S is ranked higher than
88% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. STXS: 1.10 )
STXS' s 10-Year P/S Range
Min: 0.15   Max: 35.32
Current: 1.1

0.15
35.32
EV-to-EBIT 10.80
STXS's EV-to-EBIT is ranked higher than
86% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. STXS: 10.80 )
STXS' s 10-Year EV-to-EBIT Range
Min: 19.5   Max: 668.7
Current: 10.8

19.5
668.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.30
STXS's Price/Median PS Value is ranked higher than
97% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. STXS: 0.30 )
STXS' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 4.56
Current: 0.3

0.12
4.56
Forward Rate of Return (Yacktman) -100.36
STXS's Forward Rate of Return (Yacktman) is ranked lower than
52% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. STXS: -100.36 )
STXS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.2   Max: -4
Current: -100.36

-4.2
-4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RJR1.Germany
Stereotaxis, Inc. designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. The core components of the Niobe system have received regulatory clearance in the U.S., Canada Europe, China and various other countries. In addition to the Niobe system and its components, the Company also has developed the Odyssey Total Information Solution, which consolidates the multiple sources of diagnostic and imaging information found in the interventional lab into a large-screen user interface with single mouse control, which could be connected via a private network line to other interventional labs or to a remote clinical call center. The system also features a remote viewing and recording capability, called Odyssey Cinema, which simultaneously captures procedure data from multiple sources. The tool includes an archiving capability that would allow clinicians to store and replay entire procedures or segments of procedures. This information could be accessed from locations throughout the hospital local area network and over the global Odyssey network providing physicians with a tool for clinical collaboration, remote consultation and training. The Company operates mainly in the U.S., Europe and Asia and it continues to sell its products both within and outside of the U.S. It markets its products in the U.S and internationally through a direct sales force of senior sales specialists, distributors and sales agents, supported by account managers and clinical specialists that provide training, clinical support, and other services to its customers. The markets for medical devices are intensely competitive and are characterized by rapid technological advances, frequent new product introductions, evolving industry standards and price erosion. It faces competition from companies that are developing new approaches and products for use in interventional procedures, including robotic approaches that are directly competitive with its technology. It also faces competition from companies who currently market or are developing drugs, gene or cellular therapies to treat the conditions for which the Company's products are intended.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide